Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

Leleu, Xavier; Hulin, Cyrille; Lambert, Jérôme; Bobin, Arthur; Perrot, Aurore; Karlin, Lionel; Roussel, Murielle; Montes, Lydia; Chérel, Brieuc; Chalopin, Thomas; Slama, Borhane; Chrétien, Marie‐Lorraine; Laribi, Kamel; Dingremont, C.; Roul, Christophe; Mariette, Clara; Rigaudeau, Sophie; Calmettes, Claire; Dib, Mamoun; Tiab, Mourad; Vincent, Laure; Delaunay, Jacques; Santagostino, Alberto; Macro, Margaret; Bourgeois, Emmanuelle; Orsini‐Piocelle, Frédérique; Gay, Julie; Bareau, Benoît; Bigot, Noémie; Vergez, François; Lebreton, Pierre; Tabrizi, Reza; Waultier‐Rascalou, Agathe; Frenzel, Laurent; Le Calloch, Ronan; Chalayer, Émilie; Braun, Thorsten; Lachenal, Florence; Corm, Sélim; Kennel, Celine; Belkhir, Rakiba; Blade, Jean‐Sébastien; Joly, Bertrand; Richez-Olivier, Valentine; Gardeney, Hélène; Demarquette, Hélène; Robu-Cretu, Daniela; Garderet, Laurent; Newinger-Porte, Muriel; Kasmi, Amine; Royer, Bruno; Decaux, Olivier; Arnulf, Bertrand; Belhadj, Karim; Touzeau, Cyrille; Mohty, Mohamad; Manier, Salomon; Moreau, Philippe; Avet‐Loiseau, Hervé; Corre, Jill; Façon, Thierry

doi:10.1038/s41591-024-03050-2

Public

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

Published in Nature Medicine • Jun 3, 2024

Authors:

Xavier Leleu

Cyrille Hulin

Jérôme Lambert

Abstract

Abstract CD38-targeting immunotherapy is approved in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM) that are transplant ineligible (TI) and is considered the best standard of care (SOC). To improve current SOC, we evaluated the added value of...

Subject

Lenalidomide

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!